Figure 7.
Treatment with rosiglitazone increased PON1 activity (U/ml) and reduced MPO activity (U/l) in the rosiglitazone group, compared with the AS group. (A) Serum PON1 activity. (B) Serum MPO activity. Data are presented as mean ± SEM, (n=6 in each group). ANOVA, P<0.05; *P<0.01 vs. control group; **P<0.05 vs. AS group. PON1, paraoxonase 1; MPO, myeloperoxidase; AS, atherosclerosis.